Insider Trading › FLXN › Insiders
FLXN
FLXN·Insider activity
$24.23
+0.12 (+0.51%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
FLXN
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
FLXNS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
No open-market insider purchases or sales of FLXN were filed in the last 180 days. Newest filing Jul 20, 2021 (5 years ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by FLXN insiders · Form 4 · last two years
No open-market insider buys or sells in the last two years.
On Record
$0Purchases · 180 days
$0Sales · 180 days
116Open-market transactions on record
0Insiders filing · 180 days
Purchases (code P) and sales (code S) of FLXN common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
116 on record · newest trade first
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Willwerth ChristinaChief Strategy Officer | Sale | −3,945 | $6.45 | $25K | 141.2Kdirect | Jul 19, 2021 | Jul 20, 2021 | Form 4 ↗ |
| Wentworth KerryChief Regulatory Officer | Sale | −3,944 | $6.45 | $25K | 140.4Kdirect | Jul 19, 2021 | Jul 20, 2021 | Form 4 ↗ |
| Muzikant AdamChief Business Officer | Sale | −1,870 | $6.45 | $12K | 103.7Kdirect | Jul 19, 2021 | Jul 20, 2021 | Form 4 ↗ |
| Levine Mark S.General Counsel | Sale | −3,945 | $6.45 | $25K | 133.5Kdirect | Jul 19, 2021 | Jul 20, 2021 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Sale | −2,229 | $7.23 | $16K | 220.7Kdirect | May 10, 2021 | May 12, 2021 | Form 4 ↗ |
| Layman MelissaChief Commercial Officer | Sale | −4,520 | $11.80 | $53K | 104.0Kdirect | Mar 15, 2021 | Mar 16, 2021 | Form 4 ↗ |
| Layman MelissaChief Commercial Officer | Sale | −2,624 | $12.55 | $33K | 88.4Kdirect | Jan 28, 2021 | Jan 29, 2021 | Form 4 ↗ |
| Muzikant AdamChief Business Officer | Sale | −4,005 | $11.13 | $45K | 73.5Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| KELLEY SCOTTChief Medical Officer | Sale | −6,829 | $11.13 | $76K | 113.5Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| Wentworth KerryChief Regulatory Officer | Sale | −6,829 | $11.13 | $76K | 113.8Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| Willwerth ChristinaChief Strategy Officer | Sale | −6,602 | $11.13 | $73K | 115.2Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| Levine Mark S.General Counsel | Sale | −6,829 | $11.13 | $76K | 107.4Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Sale | −6,073 | $11.13 | $68K | 151.0Kdirect | Jan 5, 2021 | Jan 7, 2021 | Form 4 ↗ |
| Stejbach MarkDirector | Purchase | +2,051 | $9.75 | $20K | 2,051direct | May 26, 2020 | May 27, 2020 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +10.3K | $9.75 | $100K | 346.6Kindirect | May 26, 2020 | May 27, 2020 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Sale | −2,413 | $10.88 | $26K | 117.1Kdirect | May 7, 2020 | May 11, 2020 | Form 4 ↗ |
| Willwerth ChristinaChief Strategy Officer | Sale | −3,533 | — | — | 52.5Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| KELLEY SCOTTChief Medical Officer | Sale | −3,724 | — | — | 49.4Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| Levine Mark S.General Counsel | Sale | −3,724 | — | — | 43.5Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| Wentworth KerryChief Regulatory Officer | Sale | −3,724 | — | — | 50.1Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Sale | −3,095 | — | — | 88.5Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Sale | −3,851 | — | — | 100.2Kdirect | Jan 3, 2020 | Jan 7, 2020 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +2,000 | $10.74 | $21K | 45.3Kindirect | Aug 8, 2019 | Aug 9, 2019 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,317 | $10.85 | $25K | 72.2Kdirect | Aug 8, 2019 | Aug 8, 2019 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Purchase | +2,500 | $11.05 | $28K | 89.4Kdirect | May 31, 2019 | Jun 3, 2019 | Form 4 ↗ |
| MERRIFIELD C ANNDirector | Purchase | +8,000 | $12.64 | $101K | 10.0Kdirect | May 23, 2019 | May 24, 2019 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Purchase | +4,000 | $11.99 | $48K | 86.9Kdirect | May 13, 2019 | May 15, 2019 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +4,012 | $12.48 | $50K | 74.9Kdirect | May 10, 2019 | May 13, 2019 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Sale | −2,248 | $10.06 | $23K | 82.9Kdirect | May 8, 2019 | May 9, 2019 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +4,046 | $12.36 | $50K | 70.9Kdirect | Mar 12, 2019 | Mar 13, 2019 | Form 4 ↗ |
| Levine Mark S.General Counsel | Sale | −734 | $12.36 | $9K | 9,060direct | Jan 3, 2019 | Jan 4, 2019 | Form 4 ↗ |
| Wentworth KerryChief Regulatory Officer | Sale | −622 | $12.36 | $8K | 11.2Kdirect | Jan 3, 2019 | Jan 4, 2019 | Form 4 ↗ |
| KELLEY SCOTTChief Medical Officer | Sale | −622 | $12.36 | $8K | 15.3Kdirect | Jan 3, 2019 | Jan 4, 2019 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Sale | −746 | $12.36 | $9K | 64.8Kdirect | Jan 3, 2019 | Jan 4, 2019 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Sale | −3,278 | $12.36 | $41K | 66.8Kdirect | Jan 3, 2019 | Jan 4, 2019 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +5,000 | $17.10 | $86K | 69.2Kdirect | Nov 9, 2018 | Nov 13, 2018 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Purchase | +4,000 | $16.56 | $66K | 48.3Kdirect | Nov 9, 2018 | Nov 13, 2018 | Form 4 ↗ |
| Arkowitz DavidChief Financial Officer | Purchase | +4,000 | $23.42 | $94K | 44.3Kdirect | Aug 9, 2018 | Aug 10, 2018 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +10.0K | $22.33 | $223K | 75.3Kdirect | Aug 9, 2018 | Aug 10, 2018 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Sale | −16.5K | $25.00 | $412K | 62.3Kdirect | Jul 3, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Sale | −33.5K | $25.10 | $841K | 78.8Kdirect | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Purchase | +1,000 | $24.66 | $25K | 1,000indirect | Nov 21, 2017 | Nov 22, 2017 | Form 4 ↗ |
| Bodick NeilChief Scientific Officer | Purchase | +1,700 | $24.39 | $41K | 64.6Kdirect | Nov 21, 2017 | Nov 22, 2017 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +5,000 | $23.60 | $118K | 35.4Kdirect | Nov 8, 2017 | Nov 9, 2017 | Form 4 ↗ |
| Deniz YamoChief Medical Officer | Purchase | +1,000 | $24.20 | $24K | 9,000direct | Sep 5, 2017 | Sep 15, 2017 | Form 4 ↗ |
| Deniz YamoChief Medical Officer | Purchase | +2,000 | $23.95 | $48K | 8,000direct | Sep 1, 2017 | Sep 15, 2017 | Form 4 ↗ |
| Deniz YamoChief Medical Officer | Purchase | +1,000 | $24.55 | $25K | 6,000direct | Sep 1, 2017 | Sep 15, 2017 | Form 4 ↗ |
| Deniz YamoChief Medical Officer | Purchase | +1,375 | $25.40 | $35K | 5,000direct | Aug 31, 2017 | Sep 15, 2017 | Form 4 ↗ |
| Stejbach MarkDirector | Purchase | +1,580 | $17.02 | $27K | 1,580indirect | Jun 16, 2017 | Jun 20, 2017 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +5,000 | $17.01 | $85K | 5,000indirect | Jun 5, 2017 | Jun 6, 2017 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +5,000 | $17.23 | $86K | 20.1Kdirect | Jun 5, 2017 | Jun 6, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −1,700 | $19.39 | $33K | 59.9Kdirect | May 15, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −5,130 | $18.81 | $96K | 61.6Kdirect | May 15, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −1,700 | $19.39 | $33K | 39.1Kdirect | May 15, 2017 | May 17, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −5,130 | $18.81 | $96K | 40.8Kdirect | May 15, 2017 | May 17, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −200 | $28.86 | $6K | 59.9Kdirect | Apr 17, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −4,800 | $28.20 | $135K | 60.1Kdirect | Apr 17, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −200 | $28.86 | $6K | 45.9Kdirect | Apr 17, 2017 | Apr 18, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −4,800 | $28.20 | $135K | 46.1Kdirect | Apr 17, 2017 | Apr 18, 2017 | Form 4 ↗ |
| DRISCOLL FREDERICK WChief Financial Officer | Sale | −3,000 | $23.00 | $69K | 7,777direct | Mar 23, 2017 | Mar 24, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −5,000 | $20.41 | $102K | 59.9Kdirect | Mar 17, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −5,000 | $20.41 | $102K | 50.9Kdirect | Mar 17, 2017 | Mar 20, 2017 | Form 4 ↗ |
| DRISCOLL FREDERICK WChief Financial Officer | Sale | −600 | $20.42 | $12K | 7,777direct | Feb 28, 2017 | Mar 2, 2017 | Form 4 ↗ |
| DRISCOLL FREDERICK WChief Financial Officer | Sale | −32.8K | $19.96 | $655K | 8,377direct | Feb 28, 2017 | Mar 2, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale Amended | −5,000 | $19.15 | $96K | 59.9Kdirect | Feb 24, 2017 | May 19, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −5,000 | $19.15 | $96K | 55.9Kdirect | Feb 24, 2017 | Feb 27, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −5,000 | $18.35 | $92K | 60.9Kdirect | Jan 20, 2017 | Jan 23, 2017 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −10.0K | $18.46 | $185K | 65.9Kdirect | Dec 21, 2016 | Dec 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +10.0K | $16.38 | $164K | 43.3Kindirect | Dec 1, 2016 | Dec 5, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +1,667 | $18.41 | $31K | 30.7Kdirect | Nov 23, 2016 | Nov 23, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +1,666 | $17.95 | $30K | 29.1Kdirect | Nov 22, 2016 | Nov 23, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +33.3K | $18.00 | $600K | 33.3Kindirect | Nov 21, 2016 | Nov 22, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +1,666 | $17.90 | $30K | 27.4Kdirect | Nov 21, 2016 | Nov 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +400 | $13.71 | $5K | 25.5Kdirect | Jun 21, 2016 | Jun 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +504 | $13.65 | $7K | 25.1Kdirect | Jun 21, 2016 | Jun 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +4,600 | $13.76 | $63K | 24.6Kdirect | Jun 21, 2016 | Jun 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +13.2K | $13.62 | $180K | 20.0Kdirect | Jun 21, 2016 | Jun 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +3,343 | $13.70 | $46K | 6,778direct | Jun 20, 2016 | Jun 22, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +3,435 | $13.98 | $48K | 3,435direct | Jun 20, 2016 | Jun 22, 2016 | Form 4 ↗ |
| MERRIFIELD C ANNDirector | Purchase | +1,000 | $13.39 | $13K | 2,000direct | Jun 14, 2016 | Jun 16, 2016 | Form 4 ↗ |
| LUBASH BARBARA N10% owner | Purchase | +4,194 | $14.00 | $59K | 20.7Kindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| LUBASH BARBARA N10% owner | Purchase | +710.1K | $14.00 | $9.9M | 3.5Mindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| Versant Development Fund III, L.P.10% owner | Purchase | +4,194 | $14.00 | $59K | 20.7Kindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| Versant Development Fund III, L.P.10% owner | Purchase | +710.1K | $14.00 | $9.9M | 3.5Mindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +4,194 | $14.00 | $59K | 20.7Kindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +710.1K | $14.00 | $9.9M | 3.5Mindirect | Jun 8, 2016 | Jun 10, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,000 | $10.41 | $21K | 13.6Kdirect | May 20, 2016 | May 23, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,000 | $9.65 | $19K | 11.6Kdirect | May 19, 2016 | May 20, 2016 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Purchase | +850 | $10.00 | $9K | 75.9Kdirect | May 19, 2016 | May 20, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,000 | $10.23 | $20K | 9,568direct | May 18, 2016 | May 19, 2016 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Purchase | +2,100 | $10.20 | $21K | 75.1Kdirect | May 18, 2016 | May 19, 2016 | Form 4 ↗ |
| DRISCOLL FREDERICK WChief Financial Officer | Purchase | +2,500 | $9.87 | $25K | 8,434direct | May 17, 2016 | May 18, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,000 | $9.73 | $19K | 7,568direct | May 17, 2016 | May 18, 2016 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Purchase | +800 | $9.60 | $8K | 73.0Kdirect | May 17, 2016 | May 18, 2016 | Form 4 ↗ |
| DRISCOLL FREDERICK WChief Financial Officer | Purchase | +2,500 | $9.19 | $23K | 5,934direct | May 16, 2016 | May 17, 2016 | Form 4 ↗ |
| Clayman Michael D.President and CEO · Director | Purchase | +2,000 | $9.51 | $19K | 5,568direct | May 16, 2016 | May 17, 2016 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Purchase | +250 | $9.70 | $2K | 72.2Kdirect | May 16, 2016 | May 17, 2016 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Purchase | +1,000 | $9.10 | $9K | 71.9Kdirect | May 16, 2016 | May 17, 2016 | Form 4 ↗ |
| MERRIFIELD C ANNDirector | Purchase | +1,000 | $23.00 | $23K | 1,000direct | Sep 11, 2015 | Sep 14, 2015 | Form 4 ↗ |
| Novo A/S10% owner | Sale | −63.4K | $20.55 | $1.3M | 2.1Mdirect | Jun 22, 2015 | Jun 22, 2015 | Form 4 ↗ |
| Novo A/S10% owner | Sale | −50.9K | $20.07 | $1.0M | 2.2Mdirect | Jun 19, 2015 | Jun 22, 2015 | Form 4 ↗ |
| Novo A/S10% owner | Sale | −35.7K | $21.51 | $768K | 2.2Mdirect | Jun 18, 2015 | Jun 22, 2015 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −1,500 | $25.76 | $39K | 70.9Kdirect | Mar 16, 2015 | Mar 16, 2015 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −2,500 | $24.99 | $62K | 72.4Kdirect | Mar 16, 2015 | Mar 16, 2015 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −4,000 | $24.26 | $97K | 74.9Kdirect | Mar 10, 2015 | Mar 11, 2015 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −4,000 | $23.45 | $94K | 78.9Kdirect | Mar 4, 2015 | Mar 5, 2015 | Form 4 ↗ |
| Bodick NeilChief Medical Officer | Sale | −4,000 | $22.44 | $90K | 82.9Kdirect | Feb 26, 2015 | Feb 26, 2015 | Form 4 ↗ |
| Novo A/S10% owner | Purchase | +500.0K | n/c | — | 2.3Mdirect | Dec 17, 2014 | Dec 18, 2014 | Form 4 ↗ |
| Sofinnova Partners SAS10% owner | Sale | −10.0K | $20.00 | $200K | 2.1Mdirect | Oct 29, 2014 | Jan 22, 2015 | Form 4 ↗ |
| Novo A/S10% owner | Purchase | +692.3K | n/c | — | 1.8Mdirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| Versant Venture Capital III, L.P.10% owner | Purchase | +1,806 | n/c | — | 3.2Mindirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| Versant Venture Capital III, L.P.10% owner | Purchase | +305.9K | n/c | — | 3.2Mdirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| Tordjman RafaelDirector · 10% owner | Purchase | +230.8K | n/c | — | 2.1Mindirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| Sofinnova Partners SAS10% owner | Purchase | +230.8K | n/c | — | 2.1Mdirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| COLELLA SAMUEL DDirector · 10% owner | Purchase | +307.7K | n/c | — | 3.2Mindirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
| Bolzon Bradley J PhDDirector · 10% owner | Purchase | +307.7K | n/c | — | 3.2Mindirect | Feb 18, 2014 | Feb 20, 2014 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →